Reversibility of established diabetic glomerulopathy by anti-TGF-β antibodies in db/db mice
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Treatment with a neutralizing anti-transforming growth factor-beta (TGF-beta) antibody can prevent the development of diabetic nephropathy in the db/db mouse, a model of type 2 diabetes. However, it is unknown whether anti-TGF-beta therapy can reverse the histological lesions of diabetic glomerulopathy once they are established. Diabetic db/db mice and their non-diabetic db/m littermates were allowed to grow until 16 weeks of age, by which time the db/db mice had developed glomerular basement membrane (GBM) thickening and mesangial matrix expansion. The mice were then treated with an irrelevant control IgG or a panselective, neutralizing anti-TGF-beta antibody for eight more weeks. Compared with control db/m mice, the db/db mice treated with IgG had developed increased GBM width (16.64+/-0.80 nm vs. 21.55+/-0.78 nm, P<0.05) and increased mesangial matrix fraction (4.01+/-0.81% of total glomerular area vs. 9.55+/-1.04%, P<0.05). However, the db/db mice treated with anti-TGF-beta antibody showed amelioration of GBM thickening (18.40+/-0.72 nm, P<0.05 vs. db/db-IgG) and mesangial matrix accumulation (6.32+/-1.79%, P<0.05 vs. db/db-IgG). Our results demonstrate that inhibiting renal TGF-beta activity can partially reverse the GBM thickening and mesangial matrix expansion in this mouse model of type 2 diabetes. Anti-TGF-beta regimens would be useful in the treatment of diabetic nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987 · cited 1×
“To favorably modify the disease course, the optimal treatment program entails a multidisciplinary approach that tries to achieve tight glycemic control [41,42], to regulate the blood pressure to 130/80mm Hg [43], to preferably use ACE inhibitors [44] or angiotensin receptor blockers [45,46], to treat hyperlipidemia [4…”
BackgroundThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Gæde, P., Vedel, P., Parving, H.-H., & Pedersen, O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07368-1 · Cited by 981 · cited 1×
“Unfortunately, even if all these measures are maximized, they may not prevent the progression of diabetic nephropathy to endstage renal disease [50].”
Background
Cited by
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
“Consistent with the major effect of PKC- being via a TGF- I-dependent pathway, no decrease in urinary albumin excretion was observed, a phenomenon similar to that seen in diabetic rodents treated with a TGF- 1-neutralizing antibody (91).”
ResultDiabetic kidney disease in the db/db mouse
Sharma, K., McCue, P., & Dunn, S. R. (2003) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00315.2002 · Cited by 521
Mediators of Diabetic Renal Disease: The Case for TGF-β as the Major Mediator
Ziyadeh, F. N. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000093460.24823.5b · Cited by 463
“Compared with control db/db mice, the db/db mice that were treated with anti– TGF- antibody showed attenuation of GBM thickening and regression of mesangial matrix accumulation (39).”
BackgroundSelf-citationThrombospondin-1 regulation of latent TGF-β activation: A therapeutic target for fibrotic disease
Murphy-Ullrich, J. E., & Suto, M. J. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.12.009 · Cited by 332
Anti–TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy
Voelker, J., Berg, P. H., Sheetz, M., Duffin, K., Shen, T., Moser, B., Greene, T., Blumenthal, S. S., Rychlik, I., Yagil, Y., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015111230 · Cited by 275
Metadata
- Authors
- Chen, S., Carmen Iglesias-de la Cruz, M., Jim, B., Hong, S. W., Isono, M., & Ziyadeh, F. N.
- Venue
- Biochemical and Biophysical Research Communications
- Publisher
- Elsevier BV
- Published
- 2003-01
- Volume
- 300
- Issue
- 1
- Pages
- 16-22
- ISSN
- 0006-291X (ISSN-L)
- OpenAlex
- W2021461358
- Cited by
- 126
- References
- 4
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reversibility of established diabetic glomerulopathy by anti-TGF-β antibodies in db/db mice. https://app.cochat.ai/papers/10.1016/s0006-291x(02)02708-0
- The paper
- Chen, S., Carmen Iglesias-de la Cruz, M., Jim, B., Hong, S. W., Isono, M., & Ziyadeh, F. N. (2003). Reversibility of established diabetic glomerulopathy by anti-TGF-β antibodies in db/db mice. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/s0006-291x(02)02708-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.